<code id='732594BD37'></code><style id='732594BD37'></style>
    • <acronym id='732594BD37'></acronym>
      <center id='732594BD37'><center id='732594BD37'><tfoot id='732594BD37'></tfoot></center><abbr id='732594BD37'><dir id='732594BD37'><tfoot id='732594BD37'></tfoot><noframes id='732594BD37'>

    • <optgroup id='732594BD37'><strike id='732594BD37'><sup id='732594BD37'></sup></strike><code id='732594BD37'></code></optgroup>
        1. <b id='732594BD37'><label id='732594BD37'><select id='732594BD37'><dt id='732594BD37'><span id='732594BD37'></span></dt></select></label></b><u id='732594BD37'></u>
          <i id='732594BD37'><strike id='732594BD37'><tt id='732594BD37'><pre id='732594BD37'></pre></tt></strike></i>

          leisure time

          leisure time

          author:Wikipedia    Page View:73977
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Obesity now affects over 1 billion people worldwide, study finds
          Obesity now affects over 1 billion people worldwide, study finds

          AdobeMorethan1billionpeople—oroneineightpeopleworldwide—arenowestimatedtohaveobesity,anewstudyfinds.

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean